Bertis Inc.

Bertis Inc. is based in South Korea (Republic Of Korea) and lists diagnostic kits on Global Trade Plaza. Its offerings include the MASTOCHECK breast cancer early diagnosis blood test, cancer early diagnostic solutions, exosome therapeutics quality control solutions, panomics analysis service and solution platform, cancer detection multiple markers tests, and biomarker diseases diagnosis blood tests. MASTOCHECK uses a patented algorithm that combines quantitative values of three protein biomarkers measured from a small blood sample to screen for early-stage breast cancer with a stated accuracy of 92%. The test was developed by a team led by Professor Dong-Young Noh of Seoul National University after analyzing approximately 600,000 proteins and received a medical device product license from the MFDS in January 2019. As of September 2023 it had been introduced to about 400 hospitals and screening institutions nationwide. The company's proteomics-based approach measures disease-specific proteins in blood and applies AI-driven algorithms for early diagnosis. Its exosome solution (Exo-PASS) provides RNA sequencing, lipidomics using UPLC and Orbitrap Exploris 480 MS, and proteomics analysis in an all-in-one package aligned with Ministry of Food and Drug Safety guidelines. The PASS platform supports academic and pharmaceutical research with pan-omics data integration, bioinformatics, and biomarker discovery and verification services. Buyers can send an enquiry through Global Trade Plaza.